Organisation paid for research Program year 2025 Source: CMS Open Payments

Coast Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,242,097

171 payments

Through program year 2025, Coast Clinical Research LLC is reported as receiving $2,242,097 in research payments, across 171 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $330,650 25
2024 Research $571,519 29
2023 Research $1,071,323 45
2022 Research $95,317 18
2021 Research $147,107 43
2020 Research $26,182 11

Breakdown

Who paid Research payments · program years 2020–2025
  1. Pfizer Inc. $1,321,385 105 payments
  2. Novavax Inc $795,120 42 payments
  3. GlaxoSmithKline, LLC. $103,793 18 payments
  4. Sanofi Pasteur Inc. $21,800 6 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $1,105,355 39 payments
  2. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults older than 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 $272,812 16 payments
  3. Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years $272,791 8 payments
  4. A Phase 3 Randomized Doubleblind Trial to Evaluate the Safety and Immunogenicity of A 20Valent Pneumococcal Conjugate Vaccine in Healthy Infants $205,641 38 payments
  5. A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M™ Adjuvant in Children 6 Months to < 12 Years of Age $153,951 12 payments
  6. A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) With Matrix-M Adjuvant in Children 6 Months to < 12 Years of Age $73,654 3 payments
  7. A Phase II, Observer-Blind, Randomized, Controlled Study to Evaluate T $53,704 9 payments
  8. A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $50,089 9 payments
  9. A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults younger than 18 Years With a Pediatric Expansion in Adolescents (12 to younger than 18 Years) at Risk for SARS-CoV-2 $21,912 3 payments
  10. Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers $21,800 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record